A Phase 3 interventional study of Tofersen in ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation, sponsored by Biogen. Completed at 30 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
Drug: Tofersen
Participants will receive a loading dose regimen followed by maintenance dosing.
Also known as: BIIB067, QALSODY
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly. TEAEs were defined as any AEs or SAE with an onset date and time that was on or after the first dose of study drug, or any pre-existing condition that worsened in severity after the first dose of study drug.
Time frame: From first dose of the study drug in the current study up to end of follow-up period (up to Week 364)
Plasma Concentration of BIIB067
Time frame: Week 4
Concentration of BIIB067 in Cerebrospinal Fluid (CSF)
Time frame: Week 4
233AS101 and 233AS102 Integrated Summary of Efficacy (ISE): Total CSF Superoxide Dismutase 1 (SOD1) Protein Ratio to Baseline
This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
Time frame: Baseline, Weeks 52, 104 and 148
233AS101 and 233AS102 ISE: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline
This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
Time frame: Baseline, Weeks 52, 104 and 148
233AS101 and 233AS102 ISE: Change From Baseline in Total Amyotropic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function). The ALSFRS-R total score was calculated as the sum of the 4 functional domain scores, ranging from 0 to 48, where higher scores representing better function. Negative change from baseline indicates disease progression. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
Time frame: Baseline, Weeks 52, 104 and 148
233AS101 and 233AS102 ISE: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC)
Vital capacity was measured by means of an SVC test, administered in the upright position. Upright SVC was determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society. The percent predicted SVC was calculated as \[observed SVC divided by predicted SVC\]\*100%. The predicted SVC was adjusted by sex, age, height, which was programmed into and performed by the equipment used. Negative change from baseline indicated worsening of respiratory capacity. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
Time frame: Baseline, Weeks 52, 104 and 148
233AS101 and 233AS102 ISE: Change From Baseline in Handheld Dynamometry (HHD) Overall Megascore
Quantitative muscle strength was evaluated using the HHD Megascore, which tests isometric strength of multiple muscles using standard participant positioning. Approximately 8 muscle groups were examined (per each side) in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
Time frame: Baseline, Weeks 52, 104 and 148
233AS101 and 233AS102 ISE: Change From Baseline in Individual Muscle Strength Assessed by HHD
Individual muscle strength was evaluated using handheld dynamometer which tests the isometric strength of multiple muscles using standard participant positioning. Eight muscle groups were examined (per each side) in both upper and lower extremities. Negative change from baseline=decreased muscle strength. The analyses was based on observed data. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses.
Time frame: Baseline, Weeks 52, 104 and 148
233AS101 and 233AS102 ISE: Time to Death or Permanent Ventilation
Permanent ventilation was defined as ≥ 22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥ 21 consecutive days. An event of permanent ventilation was based on an adjudicated event (i.e., adjudicated by the Endpoint Adjudication Committee (EAC) as having met the permanent ventilation criteria defined in the protocol). Time to death or permanent ventilation was defined as the time to the earliest occurrence of death or permanent ventilation. The start date for calculating time to death or permanent ventilation in days was date of first dose. Participants without an event were censored at the last known alive dates. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to permanent ventilation or death was summarized using the Kaplan-Meier product limit method.
Time frame: From the baseline of the study 233AS101 up to the end of the follow-up period of the current study (up to Week 364)
233AS101 and 233AS102 ISE: Time to Death
Time to death was defined as the time from first dose received in 233AS101 to death. Participants who do not meet the endpoint definition were censored at the participant's last known alive date. Only events that were adjudicated by the EAC are included. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to death was summarized using the Kaplan-Meier product limit method.
Time frame: From the baseline of the study 233AS101 up to the end of the follow-up period of the current study (up to Week 364)
Participants were enrolled and took part at the investigative sites in Belgium, Canada, France, Germany, Italy, Japan, Denmark, the United Kingdom, and the United States from 08 Mar 2017 to 12 Aug 2024.
| Milestone | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Part A and B (All Doses) |
|---|---|---|---|
| Started | 32 | 63 | 44 |
| Completed | 12 | 34 | 26 |
| Not completed | 20 | 29 | 18 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Consent withdrawn | 6 | 5 | 3 |
| Withdrew: Investigator decision | 0 | 0 | 1 |
| Withdrew: Death | 7 | 14 | 5 |
| Withdrew: Disease progression | 5 | 7 | 7 |
| Withdrew: Reason not specified | 2 | 2 | 1 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly. TEAEs were defined as any AEs or SAE with an onset date and time that was on or after the first dose of study drug, or any pre-existing condition that worsened in severity after the first dose of study drug.
| Participants | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Part A and B (All Doses) |
|---|---|---|---|
| TEAEs | 31 | 63 | 43 |
| TESAEs | 16 | 33 | 22 |
| nanograms per milliliter (ng/mL) | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) |
|---|---|---|
| Plasma Concentration of BIIB067 | 1.22 ± 0.118 | 2.05 ± 0.516 |
| ng/mL | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) |
|---|---|---|
| Concentration of BIIB067 in Cerebrospinal Fluid (CSF) | 19.35 ± 2.829 | 9.18 ± 0.711 |
This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
| ratio | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| Week 52 | 0.78 (0.64 to 0.96) | 0.67 (0.57 to 0.79) |
| Week 104 | 0.81 (0.67 to 0.97) | 0.74 (0.65 to 0.84) |
| Week 148 | 0.75 (0.61 to 0.92) | 0.79 (0.69 to 0.91) |
This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
| ratio | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| Week 52 | 0.62 (0.49 to 0.78) | 0.50 (0.42 to 0.60) |
| Week 104 | 0.41 (0.30 to 0.55) | 0.33 (0.27 to 0.42) |
| Week 148 | 0.36 (0.25 to 0.53) | 0.33 (0.26 to 0.43) |
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function). The ALSFRS-R total score was calculated as the sum of the 4 functional domain scores, ranging from 0 to 48, where higher scores representing better function. Negative change from baseline indicates disease progression. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
| score on a scale | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| Week 52 | -9.5 ± 1.46 | -5.9 ± 1.16 |
| Week 104 | -13.1 ± 2.12 | -9.4 ± 1.69 |
| Week 148 | -13.5 ± 2.28 | -9.9 ± 1.77 |
Vital capacity was measured by means of an SVC test, administered in the upright position. Upright SVC was determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society. The percent predicted SVC was calculated as \[observed SVC divided by predicted SVC\]\*100%. The predicted SVC was adjusted by sex, age, height, which was programmed into and performed by the equipment used. Negative change from baseline indicated worsening of respiratory capacity. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
| percentage of predicted volume | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| Week 52 | -18.7 ± 3.70 | -10.6 ± 2.99 |
| Week 104 | -23.7 ± 5.90 | -14.4 ± 4.46 |
| Week 148 | -18.1 ± 5.74 | -13.8 ± 4.07 |
Quantitative muscle strength was evaluated using the HHD Megascore, which tests isometric strength of multiple muscles using standard participant positioning. Approximately 8 muscle groups were examined (per each side) in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on the data collected from both 233AS101 and 233AS102 studies. This is reported as a part of the final integrated analyses. Baseline is defined as the Day 1 of 233AS101 Part C. Data has been reported for Weeks 52, 104 and 148 from the 233AS101 Part C baseline.
| score on a scale | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| Week 52 | -0.41 ± 0.101 | -0.15 ± 0.079 |
| Week 104 | -0.56 ± 0.154 | -0.42 ± 0.112 |
| Week 148 | -0.43 ± 0.089 | -0.38 ± 0.062 |
Individual muscle strength was evaluated using handheld dynamometer which tests the isometric strength of multiple muscles using standard participant positioning. Eight muscle groups were examined (per each side) in both upper and lower extremities. Negative change from baseline=decreased muscle strength. The analyses was based on observed data. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses.
| kilogram (kg) | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| Left Shoulder Flexion: Week 52 | -3.42 ± 6.671 | -0.51 ± 8.484 |
| Left Shoulder Flexion: Week 104 | 0.17 ± 5.714 | -4.16 ± 14.329 |
| Left Shoulder Flexion: Week 148 | -2.48 ± 5.075 | -4.12 ± 8.543 |
| Left Elbow Flexion: Week 52 | -3.89 ± 6.747 | -0.24 ± 8.031 |
| Left Elbow Flexion: Week 104 | -1.26 ± 7.361 | -3.12 ± 13.334 |
| Left Elbow Flexion: Week 148 | 0.65 ± 4.560 | -3.33 ± 8.753 |
| Left Wrist Extension: Week 52 | -3.66 ± 4.775 | -0.41 ± 7.170 |
| Left Wrist Extension: Week 104 | -0.86 ± 5.279 | -1.74 ± 8.517 |
| Left Wrist Extension: Week 148 | 0.95 ± 5.242 | -2.49 ± 6.086 |
| Left Abduction Index Finger (First Dorsal Interosseous): Week 52 | -0.96 ± 1.450 | -0.93 ± 4.448 |
| Left Abduction Index Finger (First Dorsal Interosseous): Week 104 | -0.63 ± 1.266 | -0.62 ± 2.279 |
| Left Abduction Index Finger (First Dorsal Interosseous): Week 148 | -0.41 ± 1.604 | -1.28 ± 4.913 |
| Left Abduction Thumb (Abductor Pollicus Brevis): Week 52 | -1.15 ± 1.486 | -0.70 ± 2.497 |
| Left Abduction Thumb (Abductor Pollicus Brevis): Week 104 | -0.69 ± 1.089 | -0.19 ± 2.382 |
| Left Abduction Thumb (Abductor Pollicus Brevis): Week 148 | -1.10 ± 2.324 | -0.78 ± 3.049 |
| Left Abduction 5th Digit (Abductor Digiti Minimi): Week 52 | -0.66 ± 1.208 | -0.49 ± 2.296 |
| Left Abduction 5th Digit (Abductor Digiti Minimi): Week 104 | -0.47 ± 1.226 | -0.50 ± 1.999 |
| Left Abduction 5th Digit (Abductor Digiti Minimi): Week 148 | -0.43 ± 1.496 | -0.66 ± 2.394 |
| Left Knee Extension: Week 52 | -4.94 ± 8.015 | 1.80 ± 10.744 |
| Left Knee Extension: Week 104 | -2.41 ± 6.545 | -1.54 ± 13.222 |
| Left Knee Extension: Week 148 | -2.48 ± 7.339 | -2.01 ± 9.711 |
| Left Ankle Dorsiflexion: Week 52 | -2.82 ± 7.560 | 0.72 ± 7.701 |
| Left Ankle Dorsiflexion: Week 104 | -5.47 ± 3.590 | -4.20 ± 11.516 |
| Left Ankle Dorsiflexion: Week 148 | -5.43 ± 5.303 | -2.33 ± 9.533 |
| Right Shoulder Flexion: Week 52 | -4.74 ± 5.494 | -0.96 ± 5.728 |
| Right Shoulder Flexion: Week 104 | -2.72 ± 4.638 | -2.81 ± 9.304 |
| Right Shoulder Flexion: Week 148 | -3.02 ± 5.066 | -3.18 ± 8.139 |
| Right Elbow Flexion: Week 52 | -4.03 ± 5.663 | -1.20 ± 7.015 |
| Right Elbow Flexion: Week 104 | -1.32 ± 6.289 | -3.04 ± 9.717 |
| Right Elbow Flexion: Week 148 | 0.49 ± 3.407 | -3.28 ± 8.704 |
| Right Wrist Extension: Week 52 | -3.82 ± 5.892 | -0.63 ± 4.870 |
| Right Wrist Extension: Week 104 | -0.76 ± 4.086 | -1.65 ± 6.267 |
| Right Wrist Extension: Week 148 | 0.09 ± 5.096 | -1.89 ± 5.033 |
| Right Abduction Index Finger (First Dorsal Interosseous): Week 52 | -0.86 ± 1.381 | -0.36 ± 1.405 |
| Right Abduction Index Finger (First Dorsal Interosseous): Week 104 | -0.38 ± 1.057 | -0.45 ± 1.569 |
| Right Abduction Index Finger (First Dorsal Interosseous): Week 148 | -0.23 ± 1.545 | -0.46 ± 1.193 |
| Right Abduction Thumb (Abductor Pollicus Brevis): Week 52 | -0.98 ± 1.425 | -1.24 ± 4.595 |
| Right Abduction Thumb (Abductor Pollicus Brevis): Week 104 | -0.31 ± 0.947 | -0.24 ± 2.016 |
| Right Abduction Thumb (Abductor Pollicus Brevis): Week 148 | -0.86 ± 1.861 | -1.10 ± 5.247 |
| Right Abduction 5th Digit (Abductor Digiti Minimi): Week 52 | -0.78 ± 1.210 | -1.12 ± 5.112 |
| Right Abduction 5th Digit (Abductor Digiti Minimi): Week 104 | -0.54 ± 1.059 | -0.21 ± 1.639 |
| Right Abduction 5th Digit (Abductor Digiti Minimi): Week 148 | -0.69 ± 1.009 | -1.36 ± 5.634 |
| Right Knee Extension: Week 52 | -4.90 ± 5.964 | 1.05 ± 8.973 |
| Right Knee Extension: Week 104 | -2.16 ± 9.453 | -3.09 ± 13.046 |
| Right Knee Extension: Week 148 | -0.19 ± 7.407 | -1.60 ± 7.685 |
| Right Ankle Dorsiflexion: Week 52 | -5.68 ± 8.907 | -1.05 ± 5.923 |
| Right Ankle Dorsiflexion: Week 104 | -5.86 ± 3.501 | -3.78 ± 13.008 |
| Right Ankle Dorsiflexion: Week 148 | -6.74 ± 7.308 | -3.40 ± 8.172 |
Permanent ventilation was defined as ≥ 22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥ 21 consecutive days. An event of permanent ventilation was based on an adjudicated event (i.e., adjudicated by the Endpoint Adjudication Committee (EAC) as having met the permanent ventilation criteria defined in the protocol). Time to death or permanent ventilation was defined as the time to the earliest occurrence of death or permanent ventilation. The start date for calculating time to death or permanent ventilation in days was date of first dose. Participants without an event were censored at the last known alive dates. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to permanent ventilation or death was summarized using the Kaplan-Meier product limit method.
| weeks | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| 233AS101 and 233AS102 ISE: Time to Death or Permanent Ventilation | NA (135.6 to NA) | NA (253.6 to NA) |
Time to death was defined as the time from first dose received in 233AS101 to death. Participants who do not meet the endpoint definition were censored at the participant's last known alive date. Only events that were adjudicated by the EAC are included. This outcome measure was not a standalone analysis for 233AS102. Analysis was performed on data collected from both 233AS101 \& 233AS102 studies. This is reported as a part of final integrated analyses. Time to death was summarized using the Kaplan-Meier product limit method.
| weeks | 233AS101 and 233AS102 (Part C): Placebo + Delayed-start BIIB067 100 mg | 233AS101 and 233AS102 (Part C): Early-start BIIB067 100 mg |
|---|---|---|
| 233AS101 and 233AS102 ISE: Time to Death | NA (NA to NA) | NA (260.7 to NA) |
Collected over From first dose of the study drug in the current study up to end of follow-up period (up to Week 364). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 233AS101: Part C (Prior Placebo) | 7/32 (21.9%) | 16/32 (50%) | 31/32 (96.9%) |
| 233AS101: Part C (Prior BIIB067 100 mg) | 14/63 (22.2%) | 33/63 (52.4%) | 63/63 (100%) |
| 233AS101: Parts A and B (All Doses) | 5/44 (11.4%) | 22/44 (50%) | 43/44 (97.7%) |
| Event | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Parts A and B (All Doses) |
|---|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 6/32 | 6/63 | 5/44 |
| Pneumonia aspirationInfections and infestations | 3/32 | 8/63 | 2/44 |
| DysphagiaGastrointestinal disorders | 1/32 | 7/63 | 3/44 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/32 | 6/63 | 0/44 |
| FallInjury, poisoning and procedural complications | 0/32 | 1/63 | 4/44 |
| ConstipationGastrointestinal disorders | 2/32 | 0/63 | 0/44 |
| PneumoniaInfections and infestations | 2/32 | 2/63 | 1/44 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/32 | 1/63 | 2/44 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/32 | 0/63 | 2/44 |
| Cardiac arrestCardiac disorders | 1/32 | 2/63 | 0/44 |
| Event | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Parts A and B (All Doses) |
|---|---|---|---|
| HeadacheNervous system disorders | 17/32 | 35/63 | 31/44 |
| FallInjury, poisoning and procedural complications | 18/32 | 25/63 | 28/44 |
| Procedural painInjury, poisoning and procedural complications | 14/32 | 33/63 | 28/44 |
| Back painMusculoskeletal and connective tissue disorders | 14/32 | 27/63 | 26/44 |
| NasopharyngitisInfections and infestations | 6/32 | 11/63 | 20/44 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 12/32 | 17/63 | 19/44 |
| Covid-19Infections and infestations | 7/32 | 26/63 | 13/44 |
| NauseaGastrointestinal disorders | 7/32 | 13/63 | 17/44 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/32 | 19/63 | 17/44 |
| DiarrhoeaGastrointestinal disorders | 12/32 | 7/63 | 7/44 |
The safety population included all participants who were enrolled and received at least one dose of study treatment in 233AS102.
| Age, Continuous(years) | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Part A and B (All Doses) | Total |
|---|---|---|---|---|
| Mean | 52.8 ± 11.00 | 48.1 ± 11.80 | 49.8 ± 11.04 | 49.7 ± 11.45 |
| Sex: Female, Male(Participants) | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Part A and B (All Doses) | Total |
|---|---|---|---|---|
| Female | 15 | 24 | 19 | 58 |
| Male | 17 | 39 | 25 | 81 |
| Ethnicity (NIH/OMB)(Participants) | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Part A and B (All Doses) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 0 | 4 |
| Not Hispanic or Latino | 25 | 40 | 26 | 91 |
| Unknown or Not Reported | 6 | 20 | 18 | 44 |
| Race/Ethnicity, Customized(Participants) | 233AS101: Part C (Prior Placebo) | 233AS101: Part C (Prior BIIB067 100 mg) | 233AS101: Part A and B (All Doses) | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Asian | 4 | 4 | 1 | 9 |
| Race — Black or African American | 0 | 1 | 0 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Race — White | 22 | 37 | 23 | 82 |
| Race — Not Reported | 6 | 20 | 18 | 44 |
| Race — Other | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Aug 2024, 89 months.
Results were first posted in Aug 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofersen